Loading…
Rare-disease biopharma with several approved drugs (Crysvita, Dojolvi, Mepsevii) and a broad gene-therapy pipeline.
Rare-disease biopharma with several approved drugs (Crysvita, Dojolvi, Mepsevii) and a broad gene-therapy pipeline.
Each medicine serves very few patients and is sold at a high price per patient, so a handful of products carry the company. Crysvita, the largest, is shared with Kyowa Kirin. Gene therapies under development are funded by that income and by share sales.
Moat: narrow (IP / patents, regulatory licence). Multiple orphan-drug approvals in ultra-rare diseases with few or no competitors.
Headquarters: Novato, California, US · Founded: 2010 · Employees: 1,371
Size Ultragenyx Pharmaceutical (RARE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.52B, the 1982nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $26.53 on 6 Nov 2026.
Performance Over six months the shares gained 21.7%, against -4.5% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 15.8% over the last twelve months (peer median +4.9%); the operating margin is -64.1% (peer median 9.1%).
Valuation It trades at 3.3× enterprise value to sales against a peer median of 6.7× (7th cheapest of 19).
Capital Return on invested capital runs 73.4 points below its cost of capital (6.1% WACC).
Short interest Short interest is 20.4% of the free float (15 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $730M | $673M | $560M | $434M | $363M |
| Revenue growth | — | +20% | +29% | +20% | — |
| Gross profit | $571M | $537M | $453M | $367M | $320M |
| EBITDA | -$434M | -$500M | -$500M | -$543M | -$631M |
| Net income | -$524M | -$575M | -$569M | -$607M | -$707M |
| Free cash flow | -$442M | -$472M | -$422M | -$519M | -$497M |
| Capital expenditure | $9.94M | $21.0M | $20.0M | $46.8M | $146M |
| Total debt | $1.19B | $1.25B | $910M | $935M | $907M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical RARE | $1.52B | +22% | +16% | -64% | 3.3× | n/a |
| BioMarin Pharmaceutical BMRN | $10.9B | +4% | +20% | 19% | 3.9× | 6.5% |
| Sanofi SAN.PA | $113B | +14% | +15% | 27% | 2.6× | -5.4% |
| Ionis Pharmaceuticals IONS | $6.55B | -48% | -7% | -68% | 7.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RARE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.8% | +0.3% | 10th highest of 21 |
| 6-month return | +21.7% | -4.5% | 6th highest of 21 |
| Distance from 52-week high | -33.5% | -19.7% | 9th lowest of 21 |
| Revenue growth (TTM) | +15.8% | +4.9% | 7th highest of 19 |
| Operating margin | -64.1% | 9.1% | 6th lowest of 19 |
| EV / Sales | 3.3× | 6.7× | 7th cheapest of 19 |
| ROIC minus cost of capital | -73.4 pp | -0.4 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | 3.3× | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 15.1× | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | 164.1× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | 13.6× | 49.9% | -13.2% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 2.3× | -8.5% | +4.6% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 3.3× | 29.6% | +29.4% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | 55.7× | n/a | n/a |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 1.5× | -5.8% | +1.9% |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 9.6× | 37.6% | +16.6% |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 3.4× | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 1.7× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | 18.4× | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | 3.7× | -4.1% | +0.2% |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | 15.5× | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 15.3× | 39.6% | +359.6% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 2.2× | -4.5% | +6.8% |